Abstract:Glioma is the most common malignant tumor in the central nervous system with no significant therapeutic breakthrough in recent years. Most attempts to apply immunotherapy in glioma have failed. Tryptophan and its metabolism can regulate malignant features of cancers and reshape immune microenvironment of tumors. However, the role of tryptophan metabolism in glioma remains unclear. In current study, we explored the relationships between the expression pattern of tryptophan metabolism-related genes (TrMGs) and tumor characteristics, including prognosis and tumor microenvironment of gliomas through analyzing 1,523 patients' samples from multiple public databases and our own cohort. Based on expression of TrMGs, K-means clustering analysis stratified all glioma patients into two clusters with significantly different TrMG expression patterns, clinicopathological features and immune microenvironment. Furthermore, we constructed a tryptophan metabolism-related genes signature (TrMRS) based on seven essential TrMGs to classify the patients into TrMRS low- and high-risk groups and validated the prognostic value of the TrMRS in multiple cohorts. Higher TrMRS represented for potentially more active tryptophan catabolism, which could subsequently lead to less tryptophan in tumor. The TrMRS high-risk group presented with shorter overall survival, and further analysis confirmed TrMRS as an independent prognostic factor in gliomas. The nomograms uniting TrMRS with other prognostic factors manifested with satisfactory efficacy in predicting the prognosis of glioma patients. Additionally, analyses of tumor immune landscapes demonstrated that higher TrMRS was correlated with more immune cell infiltration and "hot " immunological phenotype. TrMRS was also demonstrated to be positively correlated with the expression of multiple immunotherapy targets, including PD1 and PD-L1. Finally, the TrMRS high-risk group manifested better predicted response to immune checkpoint inhibitors. In conclusion, our study illustrated the relationships between expression pattern of TrMGs and characteristics of gliomas, and presented a novel model based on TrMRS for prognosis prediction in glioma patients. The association between TrMRS and tumor immune microenvironment of gliomas indicated an important role of tryptophan and its metabolism in reshaping immune landscape and the potential ability to guide the application of immunotherapy for gliomas.

Exploring MAP2K3 as a prognostic biomarker and potential immunotherapy target in glioma treatment

TREM1 As a Novel Prognostic Biomarker and Tumor Immune Microenvironment Evaluator in Glioma

CSF3R as a potential prognostic biomarker and immunotherapy target in glioma

MAPK-activated protein kinase 2 is associated with poor prognosis of glioma patients and immune inhibition in glioma

TIM-3/CD68 double-high expression in Glioma: Prognostic characteristics and potential therapeutic approaches

Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker GPSM3 in Low-Grade Gliomas

Identification of prognostic biomarkers related to retinoic acid metabolism in gliomas and analysis of their impact on the immune microenvironment

Prognostic Features of the Tumor Immune Microenvironment in Glioma and Their Clinical Applications: Analysis of Multiple Cohorts

Research Progress on the Regulation Mechanism of Key Signal Pathways Affecting the Prognosis of Glioma

MAPK9 is Correlated with a Poor Prognosis and Tumor Progression in Glioma

Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma

Exploring potential therapeutic targets for glioma based on non-targeted metabolic analysis

Alterations in the RTK/Ras/PI3K/AKT Pathway Serve As Potential Biomarkers for Immunotherapy Outcome of Diffuse Gliomas

MAPK signaling pathway-based glioma subtypes, machine-learning risk model, and key hub proteins identification

Identification of Key Immune and Cell Cycle Modules and Prognostic Genes for Glioma Patients through Transcriptome Analysis

Influence of S1PR3 expression on the glioma microenvironment and prognostic significance in low-grade gliomas

New prognostic biomarker CMTM3 in low grade glioma and its immune infiltration

Mir-484/Map2/c-myc-positive Regulatory Loop in Glioma Promotes Tumor-Initiating Properties Through ERK1/2 Signaling

CAMK1D Inhibits Glioma Through the PI3K/AKT/mTOR Signaling Pathway

Pan-cancer analysis and experimental validation of FPR3 as a prognostic and immune infiltration-related biomarker for glioma

Prognosis Prediction and Tumor Immune Microenvironment Characterization Based on Tryptophan Metabolism-Related Genes Signature in Brain Glioma